With over 30 million individuals in the United States alone affected by 7,000 rare diseases,1 it is crucial to provide these patients with timely access to diagnosis and prompt t
In today’s dynamic pharmaceutical landscape, having a high level of strategic alignment and the flawless execution of this strategy is crucial for life sciences companies aiming to establis
Digital innovation has the power to transform healthcare, but there are challenges that stand in the way of pharma companies and other providers realising their visions.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio